We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

2Seventy Bio Inc (TSVT) USD0.0001

Sell:$4.27 Buy:$4.28 Change: $0.22 (4.77%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
Change: $0.22 (4.77%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
Change: $0.22 (4.77%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.

Contact details

60 Binney Street
United States
+1 (339) 4999300

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$231.84 million
Shares in issue:
51.41 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Nick Leschly
    President, Chief Executive Officer, Director
  • William Baird
    Chief Financial Officer, Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.